Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An all inclusive, widely accepted system for correlation of indices of pathophysiology in
endometrial cancer
with a spectrum of therapeutic management has yet to be developed. Improved understanding of
tumor growth
should lead to more logical, individualized treatment especially in terms of irradiation. To support these philosophies a brief review of past reports and studies, especially the Endometrial Adjuvant Study is provided. From an analysis of 574 patients in this study, it is apparent that prognostic factors could be separated as major, differentiation, and tumor penetration and minor, number of capsules of radium and depth of uterus. A pilot study under the Gynecologic Oncology Group suggests the correlation of the major factors with lymph node involvement. Since depth of penetration and lymph node involvement are most accurately determined by surgery and pathology, surgical staging is suggested as a guide for therapeutic decision.
...
PMID:Endometrial cancer: therapeutic decision and the staging process in "early" disease. 31
The perioperative influence of leukinferon, indomethacin and their combination on the blood plasma level of thromboxane B2 (TxB2), platelet aggregation ability and humoral and cellular immunity has been assessed in 40
endometrial cancer
patients. It has been found that the perioperative use of indomethacin diminishes the blood plasma level of TxB2 and platelet aggregation ability. Leukinferon did not affect substantially the parameters. However, the combination of leukinferon with indomethacin causes a more stable reduction in platelet aggregation and TxB2 level than the use of indomethacin alone. The use of these drugs and their combination prevented postoperative immune suppression in the
endometrial cancer
patients. However, leukinferon alone or its combination with indomethacin were more effective than the use of indomethacin alone. Possible mechanisms of indomethacin and leukinferon effect on tumor cell metabolism of arachidonic acid and possible role of eicosanoids in the pathogenetic mechanisms of
tumor growth
and metastasis dissemination are discussed.
...
PMID:[The effect of indomethacin and leukinferon on the level of blood plasma thromboxane B2, platelet aggregation and the immune system of patients with endometrial cancer in the perioperative period]. 141 92
An estrogen receptor and progesterone receptor positive
endometrial carcinoma
(EnCa101) will grow in response to either estradiol or tamoxifen when transplanted into athymic mice. We have tested several antiestrogens with different properties to determine their ability to support endometrial
tumor growth
. Trioxifene, enclomiphene and nafoxidine are all as active as tamoxifen whereas the antiestrogen keoxifene, that has reduced estrogen-like properties, will partially inhibit tamoxifen-stimulated growth. Furthermore, the pure antiestrogen ICI 164,384 will block tamoxifen-stimulated growth without having any effect itself on
tumor growth
rate. Overall, the ability of antiestrogens to stimulate the growth of human
endometrial carcinoma
EnCa101 appears to be related to their intrinsic estrogenic activity.
...
PMID:Tamoxifen-stimulated growth of human endometrial carcinoma. 190 95
We investigated the efficacy of the combination of cisplatin and etoposide in
endometrial cancer
using mice bearing human
endometrial cancer
. Cisplatin (5 mg/kg) plus etoposide (10 mg/kg) caused markedly greater inhibition of the growth of medium-sized tumors (96.1% inhibition) than cisplatin alone at the same dose. Similarly, the combination of cisplatin (7.5 mg/kg) and etoposide (10 mg/kg) produced a significantly higher complete remission rate in small tumors, compared with cisplatin alone at the same dose (82.6% vs 35.3%, P less than 0.01). As a single agent, etoposide had almost no inhibitory effect on
tumor growth
and produced a considerably lower complete remission rate. Total platinum and etoposide concentrations in serum and tumor tissue were unaltered when these agents were used either singly or in combination. Our results suggested that combination cisplatin-etoposide therapy was synergistic against
endometrial cancer
.
...
PMID:Anticancer activity of the combination of cisplatin and etoposide in endometrial cancer-bearing nude mice. 202 58
A prospective study was conducted on 50 consecutive patients with stage I endometrial cancer who had primary surgical treatment. The purpose of the study was to assess the value of magnetic resonance imaging (MRI) for accurate staging of early disease and determination of myometrial invasion. Features identified by MRI were correlated with surgical pathology. Preliminary MRI results provided additional valuable information. All but one of 18 patients with histologically proven deep myometrial invasion were predicted preoperatively by MRI. Of 17 patients with detached fragments of malignant tissue in the endocervical curettage (ECC) but with results inconclusive for actual cervical invasion, MRI revealed all three patients with true cervical tissue involvement. Magnetic resonance imaging detected all six patients with gross extrauterine spread and also precisely measured uterine enlargement by myomata. The extent and location of
tumor growth
in the uterus could be mapped out in the majority of cases. Based on these findings, a pretreatment MRI scan of the pelvis in presumably stage I
endometrial carcinoma
resulted in an advance in staging in 18% of the patients, and accurately predicted deep myometrial invasion in 94% of the cases. Inclusion of MRI in the routine work-up in stage I
endometrial carcinoma
should be considered for proper clinical staging, particularly in patients with a positive but nondiagnostic ECC, uterine papillary serous carcinoma, or grade 3 tumor.
...
PMID:Magnetic resonance imaging in stage I endometrial carcinoma. 230 Mar 56
Hysterectomy specimens from 21
endometrial carcinoma
patients, who died from their disease, and 23 patients selected at random from 307 survivors, were analysed for
tumor growth
pattern and tumor cell nuclear DNA content. The results indicate that
tumor growth
pattern, reflected by the mode of infiltration, is significantly correlated to the clinical course of the disease. Patients with carcinomas exhibiting contiguous growth pattern had a better outcome than patients with discontiguously growing carcinomas. It was also found that
tumor growth
pattern correlated well with tumor nuclear DNA content. It is suggested that the pattern of infiltration of the tumors is a sensitive predictor of prognosis and that this prognostic information, which only can be obtained postoperatively, to a large extent is reflected by tumor cell nuclear DNA content in curetted diagnostic material, obtained prior to treatment.
...
PMID:The prognostic significance of growth pattern and its relation to tumor cell nuclear DNA content in endometrial carcinoma. 231 May 99
We previously showed that combined treatment with tamoxifen and progestin was effective in arresting the growth of human endometrial carcinomas in the nude mouse model. After a 15- to 20-week tumoristatic period, the tumors began to regrow, reminiscent of the clinical situation. Lack of progestin sensitivity during the regrowth period appeared to reflect the absence of progesterone receptor. To test the prediction that intermittent progestin administration may circumvent the regrowth phenomenon, the effect of various doses of progestin on blood progestin levels, EnCa 101 tumor progesterone receptor profiles, and rate of
tumor growth
were examined. Whereas 1 mg progestin was ineffective in totally down-regulating tumor progesterone receptor, 2 and 5 mg doses resulted in the total disappearance of tumor progesterone receptor by 1 week followed by its reappearance at 5 to 6 weeks and 9 to 10 weeks, respectively. On the basis of these results we predict that intermittent progestin administration may result in better control of
endometrial cancer
growth in the nude mouse system.
...
PMID:Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. 232 63
Tumors transplanted into nude mice using the TTK-1 cell lines [TTK-1(E) and TTK-1(F)] derived from normal human early decidual tissue were studied morphologically. The epithelial-like cell line TTK-1(E) and the fibroblast-like cell line TTK-1(F) were maintained in culture through one hundred and ten subcultures since July 1979. Rapidly growing tumor nodules formed at the implantation sites. The incidence of
tumor growth
was 100% for both cell lines. Histologically the tumors were composed of poorly-differentiated cells arranged in a cord-like structure and showed typical malignant characteristics. Immunohistochemical studies, electron microscopy and immunocytochemical studies revealed that the tumors from the two cell lines differed in many respects. The tumors formed by TTK-1(E) showed epithelial characteristics and the tumors formed by TTK-1(F) showed both epithelial and mesenchymal characteristics. Therefore, TTK-1(E) might be useful as an in vitro model of
endometrial cancer
and TTK-1(F) as an in vitro model of both
endometrial cancer
and endometrial stromal tumor (containing mixed mesodermal tumor). These tumors will be valuable for future studies of the tumorigenicity and therapy of uterine malignant tumors. They may reflect the various functions of decidual tissue.
...
PMID:[Ultrastructural studies of tumors transplanted into nude mice using the TTK-1 cell lines derived from normal human early decidual tissue]. 247 57
In the present study, comparison of the therapeutic effects of CDDP and the analogues (CBDCA, 254S, DWA2114R and NK121) on human gynecological carcinomas transplanted into nude mice (uterine cervical cancer; UZ-1-N,
endometrial cancer
; UE-1-N, ovarian cancer; OCl-1-N, OS-4-N and OS-8-N) was made. CDDP (5 mg/kg), CBDCA (50 mg/kg), 254S (25 mg/kg), DWA (50 mg/kg) and NK121 (18 mg/kg) were administered intraperitoneally every four days at three doses. Simultaneously the tumor size and the body weight were measured and the peripheral WBC and BUN were examined. The results were as follows: 1) The administration of 254S caused a marked inhibition of the
tumor growth
against all xenografts into nude mice. 2) CDDP and CDDP analogues except 254S were not effective against UE-1-N, but in this xenograft antitumor activity of 254S was remarkable. 3) With 254S, there were a decrease in body weight and the peripheral leukopenia and the elevation of BUN level were more severe. Although 254S has severe side effects, 254S is seemed to be recommendable for the treatment of gynecological malignancies.
...
PMID:[Comparative studies of the antitumor activities of CDDP and the analogs--using gynecological carcinomas transplanted into nude mice]. 264 7
Possible deep (more than an inner third of the uterine wall) myometrial invasion and cervical extension of
endometrial carcinoma
were evaluated prospectively using magnetic resonance (MR) and transabdominal real-time sonography (US) in 20 and 10 patients, respectively. The data obtained from these examinations were compared with hysterosalpingography (HSG) and clinical modalities including hysteroscopy, sounding and histopathologic findings after surgery. The concordance of outlining cervical extension was between MR and hysteroscopy 85 per cent, and between US and hysteroscopy 50 per cent. Deep myometrial tumor invasion was suggested in 4/10 patients by US and in 6/20 by MR, and was confirmed in all but one in each group at histologic examination of the resected uterus. There were no false negative US or MR examinations. Transabdominal US did not prove accurate in defining local
endometrial carcinoma
(distinguishing between stages I and II), but it may be used as an additional tool in revealing myometrial invasion. MR, however, seems to refine the delineation of uterine
tumor growth
.
...
PMID:Staging in local endometrial carcinoma. Assessment of magnetic resonance and ultrasound examinations. 269 68
1
2
3
4
5
6
7
8
9
10
Next >>